Suppr超能文献

低收入和中等收入国家基本心血管疾病药物的可及性和可负担性相关因素:一项系统综述

Factors associated with the availability and affordability of essential cardiovascular disease medicines in low- and middle-income countries: A systematic review.

作者信息

Lotfizadeh Ali, Palafox Benjamin, Takallou Armin, Balabanova Dina, McKee Martin, Murphy Adrianna

机构信息

PASHA, Los Angeles, California, United States of America.

Department of Health Services Research and Policy, Centre for Global Chronic Conditions, London School of Hygiene and Tropical Medicine, London, United Kingdom.

出版信息

PLOS Glob Public Health. 2022 Mar 23;2(3):e0000072. doi: 10.1371/journal.pgph.0000072. eCollection 2022.

Abstract

Despite their potential to prevent or delay the onset and progression of cardiovascular disease (CVD), medicines for CVD remain unavailable and unaffordable to many in low- and middle-income countries (LMICs). We systematically reviewed the literature to identify factors associated with availability and affordability of CVD medicines in LMICs. A protocol for this study was registered on the PROSPERO register of systematic reviews (CRD42019135393). We searched Medline, EMBASE, Global Health, Cumulative Index to Nursing and Allied Health Literature, EconLit, Social Policy and Practice, and Africa Wide Information for studies analyzing factors associated with the presence of medicines (availability) or the price of these medicines as it relates to ability to pay (affordability) in LMICs. We performed a narrative synthesis of the results using an access to medicines framework that examines influences at different levels of the health system. We did not conduct a meta-analysis because of the differences in analytic approaches and outcome measures in different studies. The search was conducted in accordance with PRISMA guidelines. Of 43 studies meeting inclusion criteria, 41 were cross-sectional. Availability and affordability were defined and measured in different ways. A range of factors such as sociodemographic characteristics, facility tier, presence of medicines on national essential medicine lists, and international subsidy programs were examined. The studies had variable quality and findings were often inconsistent. We find gaps in the literature on factors associated with availability and affordability of CVD medicines, particularly at the health program level. We conclude that there is a need for experimental and quasi-experimental studies that could identify causal factors and effective responses. Such studies would help further our understanding of how complex multifactorial influences impact these outcomes, which could inform policy decisions. Along with this, greater standardization of definitions and measurement approaches of availability and affordability are needed to allow for more effective comparisons.

摘要

尽管心血管疾病(CVD)药物有预防或延缓其发病及进展的潜力,但在低收入和中等收入国家(LMICs),许多人仍无法获得且负担不起这些药物。我们系统回顾了文献,以确定与LMICs中心血管疾病药物的可及性和可负担性相关的因素。本研究的方案已在系统评价的PROSPERO登记册(CRD42019135393)上注册。我们检索了Medline、EMBASE、Global Health、护理及相关健康文献累积索引、EconLit、社会政策与实践以及非洲广泛信息,以查找分析与LMICs中药物存在(可及性)或这些药物价格与支付能力(可负担性)相关因素的研究。我们使用药物可及性框架对结果进行了叙述性综合,该框架考察了卫生系统不同层面的影响因素。由于不同研究的分析方法和结果测量存在差异,我们未进行荟萃分析。检索按照PRISMA指南进行。在符合纳入标准的43项研究中,41项为横断面研究。可及性和可负担性的定义和测量方式各不相同。研究考察了一系列因素,如社会人口特征、机构层级、国家基本药物清单上的药物存在情况以及国际补贴计划等。这些研究质量参差不齐,结果往往不一致。我们发现关于心血管疾病药物可及性和可负担性相关因素的文献存在空白,尤其是在卫生项目层面。我们得出结论,需要进行实验性和准实验性研究,以确定因果因素和有效应对措施。此类研究将有助于我们进一步理解复杂的多因素影响如何作用于这些结果,从而为政策决策提供依据。与此同时,需要对可及性和可负担性的定义及测量方法进行更大程度的标准化,以便进行更有效的比较。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bb5/10021589/e7df654f557f/pgph.0000072.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验